# US 2010/0166732 A1 · Small streptococcus pyogenes antigens and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166732 A1
- Document ID: US20100166732A1
- Status: Published application
- Kind: A1
- Application number: 12/304,981
- Filed: 2007-07-06
- Published: 2010-07-01
- Earliest claimed: 2006-07-07
- Assignees: Intercell AG
- Inventors: Andreas Meinke; Eszter Nagy; Alexander von Gabain; Manfred Berger; Beatrice Senn; Michael Schunn
- Web page: https://patentgrep.com/patent/US20100166732A1

## CPC

- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S. pyogenes infection; a method for identifying a ligand capable of binding to said peptide; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.

## Claims

### Claim 1

A peptide consisting of one antigen of S. pyogenes selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 3 or a functional active variant of one antigen of S. pyogenes selected from the group consisting of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 3.

### Claim 2

A peptide consisting of one antigen of S. pyogenes selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 3 or a functional active variant of one antigen of S. pyogenes selected from the group consisting of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3, and
a) 0 to 350 additional amino acid residue(s) if the antigen is SEQ ID NO: 1; or
b) 0 to 200 additional amino acid residue(s) if the antigen is SEQ ID NO: 2; or
c) 0 to 100 additional amino acid residue(s) if the antigen is that of SEQ ID NO: 3; or
d) 0 to 150 additional amino acid residue(s) if the antigen is that of SEQ ID NO: 4; or
e) 0 to 450 additional amino acid residue(s) if the antigen is SEQ ID NO: 5; or
f) 0 to 250 additional amino acid residue(s) if the antigen is SEQ ID NO: 6; or
g) 0 to 250 additional amino acid residue(s) if the antigen is SEQ ID NO: 7.

### Claim 3 (depends on 1)

The peptide of claim 1 further consisting of at least one amino acid residue heterologous to the antigen.

### Claim 4 (depends on 2, 3)

The peptide of any of claim 2 or 3, wherein the additional amino acid residue(s) is/are flanking the antigen C-terminally, N-terminally or C- and N-terminally.

### Claim 5 (depends on 2)

The peptide of claim 2, wherein the functional active variant is essentially identical to any of the antigens of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3, but differs from the antigens of any of the SEQ ID NO: 4, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 3 in that it is derived from a homologous sequence of a different serotype of S. pyogenes, particularly wherein the serotype is selected from the group consisting of M2, M3, M4, M5, M6, M11, M12, M14, M19, M22, M24, M25, M28, M44, M49, M57, M59, M60, M61, M76, M83, M84, M87, M89 and M118.

### Claim 6 (depends on 2)

The peptide of claim 2, wherein the functional active variant is a portion of any of the SEQ ID NOS: 1 to 7 consisting of at least 60% of the amino acids of the antigen of any of the SEQ ID NOS: 1 to 7.

### Claim 7 (depends on 2)

The peptide of any of claim 2, wherein the functional active variant of the antigen of any of the SEQ ID NOS: 1 to 7 has at least 50% sequence identity to the antigen of any of the SEQ ID NOS: 1 to 7.

### Claim 8 (depends on 7)

The peptide of claim 7, wherein the variant is derived from the antigen of any of the SEQ ID NOS: 1 to 7 by at least one conservative amino acid substitution.

### Claim 9

A peptide comprising an amino acid sequence with at least 95% sequence identity to at least one of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7, wherein said peptide is not Spy0269, Spy0292, Spy0416A, or Spy0872.

### Claim 10 (depends on 2)

A peptide characterized in that it comprises at least 2 antigens as defined in claim 2.

### Claim 11 (depends on 2)

A nucleic acid coding for the peptide according to claim 2 or a nucleic acid complementary thereto.

### Claim 12 (depends on 11)

The nucleic acid of claim 11, wherein the nucleic acid is located in a vector.

### Claim 13 (depends on 2)

A pharmaceutical composition, especially a vaccine, comprising
(i) at least one peptide according to claim 2 or
(ii) at least one peptide comprising or consisting of the sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, and a functional active variant thereof, and
(iii) a pharmaceutically acceptable carrier or excipient.

### Claim 14 (depends on 11)

A pharmaceutical composition containing
(i) a nucleic acid according to claim 11 or a nucleic acid complementary thereto or
(ii) a nucleic acid coding for the peptide comprising or consisting of the sequence of any of the SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10, particularly a DNA sequence of any of the SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20, or a functional active variant thereof or a nucleic acid complementary thereto or the corresponding RNA sequence, and
(iii) a pharmaceutically acceptable carrier or excipient.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the nucleic acid is comprised in a vector or a cell.

### Claim 16 (depends on 1)

An antibody or functional active fragment thereof which binds specifically to the antigen of claim 1.

### Claim 17 (depends on 16)

The antibody or functional active fragment thereof of claim 16, wherein the antibody is a monoclonal, polyclonal, chimeric or humanized antibody, or wherein the functional active fragment comprises a Fab fragment.

### Claim 18 (depends on 16)

A hybridoma cell line which produces the antibody according to claim 16.

### Claim 19 (depends on 2, 16)

A method for producing an antibody according to claim 16, characterized by the following steps:
(a) administering an effective amount of the peptide according to claim 2 to an animal; and
(b) isolating the antibody produced by the animal in response to the administration of step (a) from the animal.

### Claim 20 (depends on 2, 16)

A method for producing an antibody according to claim 16, characterized by the following steps:
(a) contacting a B cell with an effective amount of the peptide according to claim 2;
(b) fusing the B cell of step (a) with a myeloma cell to obtain a hybridoma cell; and
(c) isolating the antibody produced by the cultivated hybridoma cell.

### Claim 21

(canceled)

### Claim 22 (depends on 16)

A pharmaceutical composition, especially a vaccine, comprising the antibody according to claim 16.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 13, 14, 16)

Method of immunizing a subject against an infection or treating a subject having an infection, the method comprising
(a) administering to the patient an effective amount of the peptide as defined in claim 13 or the nucleic acid as defined in claim 14 or the antibody or functional fragment thereof according to claim 16.

### Claim 26 (depends on 22)

The method of claim 22, wherein the infection is a S. pyogenes infection.

### Claim 27 (depends on 2)

A method of diagnosing a S. pyogenes infection comprising the steps of:
(a) contacting a sample obtained from a subject with the peptide according to claim 2; and
(b) detecting the presence of an antibody against S. pyogenes in the sample.

### Claim 28 (depends on 16)

A method of diagnosing a S. pyogenes infection comprising the steps of:
(a) contacting a sample obtained from a subject with the antibody according to claim 16; and
(b) detecting the presence of an antigen of S. pyogenes in the sample.

### Claim 29

(canceled)

### Claim 30

(canceled)
